Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 5Phase 3 4Phase 1 2Phase NA 1

Status

Recruiting 2Completed 2Terminated 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2Melanoma 2Small Cell Lung Carcinoma 1Primary Myelofibrosis 1Oligometastatic Disease 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

pembrolizumab 210Cyclophosphamide 122Nivolumab 109Carboplatin 92fludarabine 81Gemcitabine 76Specimen Handling 74Bevacizumab 72venetoclax 70Injections 70Magnetic Resonance Spectroscopy 67Dexamethasone 66Paclitaxel 64Biopsy 59atezolizumab 56Cisplatin 53Ipilimumab 50Temozolomide 45Docetaxel 42Azacitidine 42Pemetrexed 41Lenalidomide 41Oxaliplatin 40Rituximab 39Radiotherapy 39Fluorouracil 39Cetuximab 37durvalumab 36Cytarabine 36Capecitabine 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Tretinoin × 1 year × Clear all
NCT06536413 2026-04-03

ATRA

The Methodist Hospital Research Institute

Phase 1/2 Recruiting
42 enrolled
Plasma cell

Multiple Myeloma

NCT06439888 2025-12-01

LySATRA

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
58 enrolled
Other solid neoplasm

Oligometastatic Disease

NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
116 enrolled 36 charts
MyeloidOther hematologic neoplasmThoracic

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT04303169 2025-10-27

KEYMAKER-U02

Merck Sharp & Dohme LLC

Phase 1/2 Completed
146 enrolled
Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04305041 2025-08-29

KEYMAKER-U02

Merck Sharp & Dohme LLC

Phase 1/2 Completed
100 enrolled
Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡